CONSORT Checklist
CONSORT Checklist
CONSORT Checklist
Item Reported
Section/Topic Checklist Item
No on page No
Title and abstract
1a Identification as a randomised trial in the title
Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for
1b
abstracts)
Introduction
Background and 2a Scientific background and explanation of rationale
objectives 2b Specific objectives or hypotheses
Methods
3a Description of trial design (such as parallel, factorial) including allocation ratio
Trial design
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons
4a Eligibility criteria for participants
Participants
4b Settings and locations where the data were collected
The interventions for each group with sufficient details to allow replication, including how and when
Interventions 5
they were actually administered
Completely defined pre-specified primary and secondary outcome measures, including how and when
6a
Outcomes they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
7a How sample size was determined
Sample size
7b When applicable, explanation of any interim analyses and stopping guidelines
Randomisation:
Sequence 8a Method used to generate the random allocation sequence
generation 8b Type of randomisation; details of any restriction (such as blocking and block size)
Allocation Mechanism used to implement the random allocation sequence (such as sequentially numbered
concealment 9 containers), describing any steps taken to conceal the sequence until interventions were assigned
mechanism
Who generated the random allocation sequence, who enrolled participants, and who assigned
Implementation 10
participants to interventions
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we
also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and
pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.